Enter a phrase above to search files and articles within the site.
Typically materials that are more than 5 years old will be archived
Displaying 1 - 11 of 11 results
Pemphigus
https://www.niams.nih.gov/health-topics/pemphigus
What is pemphigus? Pemphigus is a rare disease that causes blistering on many parts of the body, including the skin and the inside of the mouth, nose, throat, eyes, and genitals. In pemphigus, the immune system mistakenly attacks cells in the top layer of the skin.
Scleroderma
https://www.niams.nih.gov/health-topics/scleroderma
What is scleroderma? Scleroderma is an autoimmune connective tissue and rheumatic disease that causes inflammation in the skin and other areas of the body. This inflammation leads to patches of tight, hard skin. Scleroderma involves many systems in your body. A connective tissue disease is one that affects tissues such as skin, tendons, and cartilage. There are two major types of scleroderma: Localized scleroderma only affects the skin and the structures directly under the skin. Systemic scleroderma, also called systemic sclerosis, affects many systems in the body. This is the more serious type of scleroderma and can damage your blood
Vitiligo
https://www.niams.nih.gov/health-topics/vitiligo
What is vitiligo? Vitiligo is a chronic (long-lasting) disorder that causes areas of skin to lose color. When skin cells that make color are attacked and destroyed, the skin turns a milky-white color. No one knows what causes vitiligo, but it may be an autoimmune disease. In people with autoimmune diseases, the immune cells attack the body’s own healthy tissues by mistake, instead of viruses or bacteria. A person with vitiligo sometimes may have family members who also have the disease. There is no cure for vitiligo, but treatment may help skin tone appear more even.
Sjögren’s Syndrome
https://www.niams.nih.gov/health-topics/sjogrens-syndrome
What is Sjögren’s syndrome? Sjögren’s syndrome is a chronic (long-lasting) disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body. The main symptoms are dry eyes and mouth, but the disorder may affect other parts of the body. Many people with Sjogren’s syndrome say they feel tired often (fatigue). They also may have joint and muscle pain. In addition, the disease can damage the lungs, kidneys, and nervous system.
Rheumatoid Arthritis
https://www.niams.nih.gov/health-topics/rheumatoid-arthritis
What is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic (long-lasting) disease that mostly affects joints, such as the wrist, hands, feet, spine, knees, and jaw. In joints, RA causes inflammation that leads to: Pain. Swelling Stiffness. Loss of function. Rheumatoid arthritis is an autoimmune disorder because the immune system attacks the healthy joint tissues. Normally, the immune system helps protect the body from infection and disease. RA may cause you to feel unusually tired, to have occasional fevers, and to have a loss of appetite. It also may cause other medical problems in the heart, lungs, blood, nerves, eyes
Novel Insights Into Causes of Scleroderma Offer Potential New Treatment Strategies
https://www.niams.nih.gov/newsroom/spotlight-on-research/novel-insights-scleroderma
Integrins, a large class of cell surface molecules, play a role in a skin disease called scleroderma, according to research funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases and published in the journal Nature. The study showed that targeting integrins in mice with a form of scleroderma reversed the skin abnormalities associated with the disease. Scleroderma is a potentially life-threatening condition in which previously healthy people develop scarring of the skin, and in some cases damage to blood vessels and internal organs. In most forms of scleroderma, the cause of the disease is
New rheumatoid arthritis drug targets NIH-discovered protein
https://www.niams.nih.gov/newsroom/press-releases/rheumatoid-arthritis-drug-targets-protein
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
Modified Protein Improves Vitiligo Symptoms in Mice
Altering a key protein involved in the development of vitiligo may protect against—or even reverse—the pigmentation loss associated with the skin disorder in mice, according to recent research funded by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, and published in the journal Science Translational Medicine. Vitiligo is a progressive autoimmune disease in which the skin cells that impart color (melanocytes) are destroyed, resulting in white patches on the face, hands and other parts of the body. Scientists are unsure what causes vitiligo. They are investigating the biological mechanisms that trigger the disease, as well as its
International Team Identifies Biomarker for Scleroderma
A higher level of a small signaling molecule correlates with a more severe form of scleroderma, a chronic autoimmune disorder that involves the abnormal growth of connective tissue, according to a study funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases and published in The New England Journal of Medicine. The findings suggest that the molecule, CXCL4, could be used as a diagnostic marker for the disease and as a therapeutic target. Scleroderma is an autoimmune disease characterized by damage to blood vessels and thickening and scarring of the skin. In some cases, internal
Accelerating Medicines Partnership® (AMP®) Program
https://www.niams.nih.gov/grants-funding/funded-research/accelerating-medicines
The AMP® RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.